Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Taysha Gene Therapies, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 59 | 54 | −5 |
| Shares | 14.7M | 13.9M | −771.5K (−5.2%) |
| Value | $54.7M | $27.0M | −$27.7M (−50.6%) |
New holders (3)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Bordeaux Wealth Advisors LLC | 10,000 | $19.0K | 0.01% |
| China Universal Asset Management Co., Ltd. | 385 | $1.00K | 0.00% |
| Simplex Trading, LLC | 347 | $0 | 0.00% |
Sold out (8)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Marshall Wace, LLP | 91,670 | $341.0K |
| Davenport & Co LLC | 27,170 | $101.0K |
| Susquehanna International Group, LLP | 21,163 | $79.0K |
| Trexquant Investment LP | 19,548 | $73.0K |
| AQR Capital Management LLC | 10,134 | $38.0K |
| Captrust Financial Advisors | 821 | $3.00K |
| New York State Common Retirement Fund | 191 | $1.00K |
| Credit Suisse AG | 12 | $0 |